PROK has beaten earnings in its last two reports, but extreme cash burn, declining revenue, a confirmed technical downtrend, and an analyst target flagged as implausible keep the quality-driven exit call in place.
Thesis pillars
- Extreme Cash Burn Quality Risk→Stable
- Declining Revenue Trend→Stable
- Confirmed Technical Downtrend→Stable
- +2 more pillars — see the Why tab for full reasoning
ProKidney Corp. (PROK) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $2.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend.
ProKidney is a late-clinical-stage biotechnology company developing rilparencel, an autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes — the only cell therapy currently in Phase 3 testing for this... Read more
Sell if holding. Engine safety override at $2.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 72. Score 4.2/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About ProKidney Corp.
About ProKidney Corp.
ProKidney's rilparencel, an autologous cell therapy prepared from a patient's own kidney biopsy, is the only cell therapy in Phase 3 development for advanced chronic kidney disease and type 2 diabetes, running as the roughly 470-patient PROACT 1 trial across the United States, Mexico and Taiwan. The FDA has granted rilparencel regenerative medicine advanced therapy designation and confirmed in a 2025 Type B meeting that eGFR slope can support an accelerated-approval Biologics License Application.
ProKidney has no approved product and generates no product revenue; its entire near-term value rests on rilparencel's clinical and regulatory progress. The company manufactures rilparencel at its own cGMP facility in Winston-Salem, North Carolina, processing a small biopsy of each patient's diseased kidney into a personalized, cryopreserved cell product before shipping it back for percutaneous injection — a workflow the 10-K says has capacity to supply both the ongoing PROACT 1 trial and a potential commercial launch. A completed Phase 2 trial, REGEN-007, showed the annual decline in eGFR slope improving 78% in the group dosed on the same three-month schedule used in PROACT 1, with no rilparencel-related serious adverse events among the 49 dosed patients. ProKidney reported net losses of $151.6 million in 2025 and $163.3 million in 2024, funding operations through equity issuance rather than product sales or a disclosed commercial partner.
Show full overview
ProKidney's valuation is a binary bet on a single trial: PROACT 1's surrogate-endpoint readout is not expected until the second quarter of 2027, with the confirmatory time-to-event endpoint following in the second half of 2029, so the company must fund roughly two more years of operations before the first meaningful efficacy signal arrives. Management states its $270 million in cash and short-term investments as of December 31, 2025 should last into mid-2027 — a runway that just reaches the surrogate readout but leaves no cushion before the confirmatory data, if PROACT 1 succeeds, would still be years away.
See also: Healthcare · Biotechnology
From ProKidney Corp.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — ProKidney Corp.
Latest news
- NEWS AEVEX, Abivax, Watts Water Technologies And Other Big Stocks Moving Higher On Tuesday — benzinga Jun 30, 2026 neutral
Generated 2026-07-06T17:22:17Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinerilparencel10-K Item 1: 'Our lead product candidate, rilparencel, is the only cell therapy in Phase 3 clinical study for the treatment of advanced CKD and type 2 diabetes.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Revenue shrinking — -1.7% YoY. Growth thesis broken unless recovery story develops.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $2.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.2/10. Specifically: High short interest: 12%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 72. Prior stop was $1.93. Score 4.2/10, moderate confidence.
Take-profit target: $2.20 (+6.0% upside). Prior stop was $1.93. Stop-loss: $1.93.
Concentration risk — Pipeline: rilparencel; DATA_ISSUE: analyst_target_implausible (raw $6.25 vs price $2.08 — ratio 3.0×). Rejected, falling back to technical TP.; Quality below floor (2.8 < 4.0).
ProKidney Corp. trades at a P/E of N/A (forward -3.5). TrendMatrix value score: 5.0/10. Verdict: Sell.
15 analysts cover PROK with a consensus score of 3.9/5. Average price target: $6.
What does ProKidney Corp. do?ProKidney is a late-clinical-stage biotechnology company developing rilparencel, an autologous cell therapy designed to...
ProKidney is a late-clinical-stage biotechnology company developing rilparencel, an autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes — the only cell therapy currently in Phase 3 testing for this indication. The pre-revenue company is running the roughly 470-patient PROACT 1 Phase 3 trial toward a surrogate-endpoint readout in the second quarter of 2027, funded by $270 million in cash as of December 31, 2025.